Wells Fargo Boosts RAPT Therapeutics (RAPT) PT to $48 on Promising Anti-IgE Drug Data
RAPT Therapeutics Inc. (NASDAQ:RAPT) is one of the hot stocks to buy with huge upside potential.
Rapt Therapeutics Inc. (RAPT)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | OrbiMed Advisors Samuel Isaly | 1,086,618 | $28,023,878 | -34% | 0.66% |
| 2. | Boone Capital Daniel Walter Boone Iv | 782,461 | $20,179,669 | 6.62% | |
| 3. | Deep Track Capital David Kroin | 751,422 | $19,379,173 | 0.54% | |
| 4. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 623,282 | $16,074,443 | -35% | 0.56% |
| 5. | Ikarian Capital Neil Shahrestani | 615,000 | $15,860,850 | 1.6% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.05 | 2,500 | $50,125.00 | 6,500 | 2023-03-14 | Filing | |
| $19.95 | 600 | $11,970.00 | 14,900 | 2023-03-14 | Filing | |
| $18.48 | 400 | $7,392.00 | 14,300 | 2023-03-14 | Filing | |
| $18.75 | 1,500 | $28,125.00 | 13,900 | 2023-03-14 | Filing | |
| $12.45 | 63 | $784.66 | 42,189 | 2022-05-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.78 | 898 | $20,456.44 | 27,820 | 2024-01-05 | Filing | |
| $21.68 | 2,500 | $54,200.00 | 15,020 | 2023-12-21 | Filing | |
| $13.72 | 1,500 | $20,580.00 | 17,520 | 2023-11-28 | Filing | |
| $15.77 | 2,500 | $39,425.00 | 18,789 | 2023-10-03 | Filing | |
| $18.92 | 2,500 | $47,300.00 | 21,289 | 2023-08-18 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,794,000 | $72,057,260 | 9.68% | |
| 2. | 1,636,275 | $42,199,532 | 2.08% | |
| 3. | 1,562,500 | $40,296,875 | 15.57% | |
| 4. | 1,470,499 | $37,924,169 | 0.47% | |
| 5. | 696,188 | $17,954,688 | 0% |
News See All
15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers
The U.S. Federal Reserve conducting a 50 basis point interest rate cut was the catalyst that stocks needed to bounce back from a period of stagnation.
Should You Sell Your Stake in RAPT Therapeutics (RAPT)?
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” first-quarter 2024 investor letter.
What Makes RAPT Therapeutics (RAPT) an Investment Choice?
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here.
5 Best Biotech and AI Stocks To Buy According To Billionaire Jim Simons
In this article, we discuss 5 stock picks of Jim Simons’ Euclidean Capital.
10 Best Growth Stocks for 2022
The optimism surrounding the global economic recovery has been dented by supply chain concerns and rising inflation.
Yale University Stock Portfolio: Top 10 Picks
Yale University is one of the richest academic institutions across the world, boasting an endowment value of more than $42 billion at the end of June 2021, up from $31 billion at the end of the second...
5 Pharmaceutical Stocks to Buy According to Jim Simons’ Euclidean Capital
Below is the list of 5 pharmaceutical stocks to buy according to Jim Simons’ Euclidean Capital.
Hedge Funds Are Piling Into RAPT Therapeutics, Inc. (RAPT)
With the second-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the third ...
11 Best Pharma and Biotech Stocks to Buy According to Jim Simons' Euclidean Capital
In this article, we will discuss the 11 best pharma and biotech stocks to buy according to Jim Simons' Euclidean Capital.
Hedge Fund Resource Center Billionaire Hedge Funds
